MongoDB (MDB) Buy Rating Maintained by Analysts at Needham; The TP is $43.0; Regeneron Pharmaceuticals Has 1.17 Sentiment

March 14, 2018 - By Dolores Ford

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, makes, and commercializes medicines for the treatment of serious medical conditions worldwide. The company has market cap of $36.63 billion. The Company’s products include EYLEA injection for the treatment of neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and ARCALYST injection for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and childrenÂ’s. It has a 32.93 P/E ratio. It also markets Kevzara injection for the treatment of rheumatoid arthritis in adults; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer.

Among 8 analysts covering MongoDB (MDB), 5 have Buy rating, 0 Sell and 3 Hold. Therefore 63% are positive. MongoDB has $40.0 highest and $30 lowest target. $34.83’s average target is -12.63% below currents $39.8652 stock price. MongoDB had 10 analyst reports since October 23, 2017 according to SRatingsIntel. The firm earned “Equal-Weight” rating on Tuesday, January 30 by Morgan Stanley. Needham upgraded the shares of MDB in report on Wednesday, February 14 to “Buy” rating.

Ratings analysis reveals 50% of Regeneron Pharma’s analysts are positive. Out of 4 Wall Street analysts rating Regeneron Pharma, 2 give it “Buy”, 1 “Sell” rating, while 1 recommend “Hold”. The lowest target is $300.0 while the high is $598.0. The stock’s average target of $449 is 31.88% above today’s ($340.47) share price. REGN was included in 4 notes of analysts from November 7, 2016. RBC Capital Markets maintained Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) rating on Friday, January 6. RBC Capital Markets has “Outperform” rating and $598.0 target. Credit Suisse upgraded the shares of REGN in report on Tuesday, December 20 to “Outperform” rating. On Thursday, February 16 the stock rating was downgraded by Goldman Sachs to “Neutral”. Chardan Capital Markets maintained Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) rating on Monday, November 7. Chardan Capital Markets has “Sell” rating and $300.0 target.

Lagoda Investment Management L.P. holds 9% of its portfolio in Regeneron Pharmaceuticals, Inc. for 55,717 shares. Senzar Asset Management Llc owns 77,300 shares or 8.44% of their US portfolio. Moreover, Dsm Capital Partners Llc has 6.73% invested in the company for 1.06 million shares. The Florida-based Polen Capital Management Llc has invested 4.94% in the stock. Sustainable Growth Advisers Lp, a Connecticut-based fund reported 667,501 shares.

Analysts await Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to report earnings on May, 3. They expect $5.08 earnings per share, up 135.19% or $2.92 from last year’s $2.16 per share. REGN’s profit will be $546.58 million for 16.76 P/E if the $5.08 EPS becomes a reality. After $4.46 actual earnings per share reported by Regeneron Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 13.90% EPS growth.

Since January 1, 0001, it had 0 insider buys, and 3 sales for $1.94 million activity.

The stock increased 0.81% or $2.72 during the last trading session, reaching $340.47. About 219,871 shares traded. Regeneron Pharmaceuticals, Inc. (REGN) has risen 17.40% since March 14, 2017 and is uptrending. It has outperformed by 0.70% the S&P500.

The stock increased 5.30% or $2.0052 during the last trading session, reaching $39.8652. About 739,313 shares traded or 156.18% up from the average. MongoDB, Inc. (MDB) has 0.00% since March 14, 2017 and is . It has underperformed by 16.70% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: